Willis Johnson & Associates, Inc. Ardelyx, Inc. Transaction History
Willis Johnson & Associates, Inc.
- $1.32 Billion
- Q1 2025
A detailed history of Willis Johnson & Associates, Inc. transactions in Ardelyx, Inc. stock. As of the latest transaction made, Willis Johnson & Associates, Inc. holds 10,000 shares of ARDX stock, worth $39,200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$39,200
Previous $51,000
3.92%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ARDX
# of Institutions
235Shares Held
164MCall Options Held
490KPut Options Held
2.35M-
Janus Henderson Group PLC London, X025MShares$97.9 Million0.07% of portfolio
-
Black Rock Inc. New York, NY17.6MShares$68.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15MShares$58.8 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C311.2MShares$43.7 Million0.07% of portfolio
-
State Street Corp Boston, MA10.2MShares$39.9 Million0.0% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $606M
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...